Company Website

Contact Information:

Holly Wayne
(608) 852-0739
hwayne@rigel.com

Sara Tungseth
(701) 425-2700
skovach-tungseth@rigel.com
 

Virtual Exhibit Hall Home

Rigel Pharmaceuticals is a biotechnology company dedicated to improving the lives of patients through the discovery, development, and commercialization of novel small molecule drugs. Rigel is focused on immune and hematologic disorders, cancer, and rare diseases and see great opportunity to help patients who have diseases where few to no approved treatment options exist.

Rigel's first FDA approved product TAVALISSE® (fostamatinib disodium hexahydrate) tablets was approved in 2018.
Please visit www.TAVALISSEhcp.com to see the full Prescribing Information and learn more.

Additional Information:

Dosing and Administration Guide
TAVALISSE Together - Patient Support
TAVALISSE 2nd Line Data